The KCNK3 Knockout 786-O Polyclonal Cells comprise a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the human 786-O renal clear cell adenocarcinoma cell line, designed for targeted loss-of-function studies of the KCNK3 gene product, the TASK-1 (K2P3.1) background potassium channel. This product provides a heterogeneous pool of edited cells, reflecting the complexity of tumor cell populations, and is suitable for investigating TASK-1-dependent signaling mechanisms without clonal selection artifacts. The polyclonal knockout model enables robust assessment of gene function, pathway interrogation, and drug target validation in a clinically relevant renal cancer context. Researchers can employ this tool to dissect how KCNK3 disruption modulates cellular excitability and downstream signaling cascades.
The host 786-O cell line is a widely used model of clear cell renal cell carcinoma (ccRCC), originally derived from a primary human renal adenocarcinoma. These cells harbor biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene, leading to constitutive stabilization of hypoxia-inducible factor 2-alpha (HIF-2??) under normoxic conditions, thereby mimicking a persistent hypoxia-like transcriptional program. The tumorigenic and epithelial nature of 786-O cells make them a relevant platform for studying pathways driving ccRCC progression, including metabolic adaptation, angiogenesis, invasion, and therapeutic resistance. Their well-characterized genetics and signaling networks provide a defined background for investigating the role of KCNK3 in renal oncogenesis.
KCNK3 encodes TASK-1, a member of the two-pore domain potassium channel family that mediates leak potassium currents essential for setting the resting membrane potential and regulating cellular excitability. TASK-1 is sensitive to a wide range of physiological and pharmacological stimuli, including hypoxia, extracellular pH, volatile anesthetics, and neurohormonal regulators such as angiotensin II and endothelin-1. In the VHL-deficient 786-O backdrop, TASK-1 activity is influenced by HIF-2?? and contributes to the control of calcium influx through voltage-gated L-type calcium channels. This calcium entry activates calcineurin, which dephosphorylates and promotes nuclear translocation of NFAT transcription factors, and also triggers the ERK1/2 mitogen-activated protein kinase cascade. TASK-1 additionally forms functional complexes with auxiliary proteins including 14-3-3 scaffolds, the p11/Annexin A2 subunit, and the related TASK-3 (KCNK9) channel, and is subject to SUMO-1 modification, all of which fine-tune its trafficking and activity.
In the context of ccRCC, TASK-1 sits at a signaling crossroads between hypoxic sensing and oncogenic outputs. VHL loss and HIF-2?? accumulation in 786-O cells upregulate numerous genes involved in proliferation and migration, and TASK-1 may serve as a conduit linking membrane potential changes to these transcriptional and kinase responses. Knockout of KCNK3 in these cells is anticipated to depolarize the membrane, reduce calcineurin/NFAT and ERK1/2 activity, and alter HIF target gene expression profiles, consequently affecting cell proliferation, migration, and invasive capacity. The polyclonal nature of this knockout product preserves the genetic and phenotypic diversity of the parental population, enabling experiments that account for clonal variation and more accurately mirror intratumoral heterogeneity often observed in patient tumors.
This KCNK3 knockout tool is applicable to a broad range of experimental modalities. Electrophysiological characterization can be performed using patch-clamp recordings to directly assess potassium current attenuation and membrane potential changes. Calcium imaging assays can quantify altered intracellular calcium dynamics, while immunoblotting and RT-qPCR can probe downstream effectors such as phospho-ERK1/2, NFAT target genes, and HIF-2?? transcriptional signatures. Cell-based functional assays including MTT proliferation, wound-healing migration, and transwell invasion can evaluate phenotypic consequences. For translational studies, the engineered cells can be employed in xenograft models to assess tumor growth and metastasis in vivo. These applications make the KCNK3 Knockout 786-O Polyclonal Cells a versatile platform for dissecting potassium channel biology in renal cell carcinoma. For additional technical information or experimental protocols, please contact Ascent Research.
